```
=> file medline embase biosis biotechds scisearch hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 11:55:42 ON 03 SEP 2004

FILE 'EMBASE' ENTERED AT 11:55:42 ON 03 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:55:42 ON 03 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHDS' ENTERED AT 11:55:42 ON 03 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'SCISEARCH' ENTERED AT 11:55:42 ON 03 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'HCAPLUS' ENTERED AT 11:55:42 ON 03 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s human protein kinase and dna
L1          502 HUMAN PROTEIN KINASE AND DNA

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2          374 DUP REM L1 (128 DUPLICATES REMOVED)

=> s l2 and phosphatase
L3           12 L2 AND PHOSPHATASE

=> focus l3
PROCESSING COMPLETED FOR L3
L4           12 FOCUS L3 1-

=> d l4 1-12 ibib ab

L4   ANSWER 1 OF 12  HCAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2003:58692  HCAPLUS
DOCUMENT NUMBER:          138:119302
TITLE:                    Identification, cloning, sequences and drug screening
                          use of human protein
                          kinase/protein phosphatase homologs
INVENTOR(S):              Ota, Toshio; Isogai, Takao; Nishikawa, Tetsuo;
                          Hayashi, Koji; Otsuka, Kaoru; Yamamoto, Jun-ichi;
                          Ishii, Shizuko; Sugiyama, Tomoyasu; Wakamatsu, Ai;
                          Nagai, Keiichi; Otsuki, Tetsuji; Funahashi, Shin-ichi;
                          Senoo, Chiaki; Nezu, Jun-ichi
PATENT ASSIGNEE(S):       Japan
SOURCE:                   U.S. Pat. Appl. Publ., 78 pp., Cont.-in-part of WO
                          2001 9,316.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   12
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
     US 2003017480        A1    20030123    US 2002-60065           20020129
     JP 2002171977        A2    20020618    JP 2000-196309          20000626
     WO 2001009316        A1    20010208    WO 2000-JP5061          20000728
```

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001009319 A1 20010208 WO 2000-JP5065 20000728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CL, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1205549 A1 20020515 EP 2000-948282 20000728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.:

JP 1999-248036	A	19990729
US 1999-159590P	P	19991018
JP 2000-118776	A	20000111
US 2000-183322P	P	20000217
JP 2000-183767	A	20000502
JP 2000-241899	A	20000609
WO 2000-JP5061	A2	20000728
WO 2000-JP5065	W	20000728

AB Selection of clones having the **human protein kinase** and/or protein **phosphatase**-like structure from clones which had been isolated and the structures thereof had been detd. in the Helix Research Institute (helix clones; Japanese Patent Application No. 2000-183767) was conducted. The present inventors carried out homol. search for all the helix clones using the amino acid sequences of known kinases and phosphatases as queries, and selected 2 clones: "C-NT2RP3001938" and "C-OVARC1000945" (hereinafter referred to as "KP clones"). These KP clones contain full-length cDNAs encoding novel human proteins. It has been known that many of known kinases and phosphatases are assocd. with a variety of signal transduction pathways in cells. Therefore, there is the possibility that the newly found KP clones having the kinase/**phosphatase**-like structure are also assocd. with some signal transduction pathways. The physiol. functions of the KP clones can be tested by using reporter gene assay systems capable of detecting signal transduction. The KP clones tissue expression profile was analyzed by hybridization using high d. **DNA**. The expression level of "C-OVARC1000945" was reduced 4 h or 24 h after UV ray irradn., suggesting that it is a clone assocd. with UV ray disorders. The proteins of the present invention are useful as target mols. in drug discovery and in the development of new pharmaceuticals.

L4 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:757220 HCAPLUS
DOCUMENT NUMBER: 139:272070
TITLE: Novel cDNAs encoding **human protein kinase**, **phosphatase**, and protease family members and their diagnostic and therapeutic uses
INVENTOR(S): Meyers, Rachel E.; Olandt, Peter J.; Kapeller-Libermann, Rosana; Curtis, Rory A. J.; Williamson, Mark; Weich, Nadine
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 520 pp., Cont.-in-part of U.S. Ser. No. 45,367.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 39
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003180930	A1	20030925	US 2002-170789	20020613
WO 2001064905	A2	20010907	WO 2001-US6525	20010228
WO 2001064905	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002042099	A1	20020411	US 2001-797039	20010228
US 6730491	B2	20040504		
WO 2001066763	A2	20010913	WO 2001-US7074	20010305
WO 2001066763	A3	20020321		
WO 2001066763	C2	20031023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001066765	A2	20010913	WO 2001-US7138	20010305
WO 2001066765	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002022249	A1	20020221	US 2001-801275	20010306
US 2002086296	A1	20020704	US 2001-801267	20010306
WO 2001079473	A2	20011025	WO 2001-US40483	20010411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001090325	A2	20011129	WO 2001-US16549	20010521
WO 2001090325	A3	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002009779 A1 20020124 US 2001-861801 20010521
WO 2001096544 A2 20011220 WO 2001-US19269 20010615
WO 2001096544 A3 20020502

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002151005 A1 20021017 US 2001-882166 20010615
WO 2002016588 A2 20020228 WO 2001-US26052 20010821
WO 2002016588 A3 20030130

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002192204 A1 20021219 US 2001-934406 20010821
WO 2002026802 A2 20020404 WO 2001-US29904 20010924
WO 2002026802 A3 20030313

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002156005 A1 20021024 US 2001-961721 20010924
US 2002165152 A1 20021107 US 2001-45367 20011107
WO 2003027308 A2 20030403 WO 2002-US30054 20020923

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2000-186061P P 20000229
US 2000-187420P P 20000307
US 2000-187454P P 20000307
US 2000-197508P P 20000418
US 2000-205508P P 20000519
US 2000-212078P P 20000615
US 2000-226740P P 20000821
US 2000-235023P P 20000925
US 2000-246561P P 20001107
US 2001-797039 A2 20010228
WO 2001-US6525 A 20010228
WO 2001-US7074 A 20010305

WO 2001-US7138	A	20010305
US 2001-801267	A2	20010306
US 2001-801275	A2	20010306
US 2001-829671	A2	20010410
WO 2001-US40483	A	20010411
US 2001-861801	A2	20010521
WO 2001-US16549	A	20010521
US 2001-882166	A2	20010615
WO 2001-US19269	A	20010615
US 2001-934406	A2	20010821
WO 2001-US26052	A	20010821
US 2001-961721	A2	20010924
WO 2001-US29904	A	20010924
US 2001-45367	A2	20011107
US 2001-961656	A	20010924

AB The invention provides eleven isolated nucleic acids mols., designated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, and 23436 nucleic acid mols., which encode novel **human protein kinase** family members, serine/threonine protein kinase family members, hexokinase family members, serine/threonine **phosphatase** family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid mols., recombinant expression vectors contg. 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 nucleic acid mols., host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted. The invention still further provides isolated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 proteins, fusion proteins, antigenic peptides and anti-2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 antibodies. Diagnostic methods utilizing compns. of the invention are also provided.

L4 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2003:232419 HCAPLUS
DOCUMENT NUMBER:	139:393753
TITLE:	Human Cdr2 kinase is involved in the UV-induced **DNA** damage checkpoint function
AUTHOR(S):	Lu, Rui
CORPORATE SOURCE:	Dep. Biochem. Cell Bio., Grad. Sch. Med. Sci., Nagoya City Univ., Japan
SOURCE:	Nagoya-shiritsu Daigaku Igakkai Zasshi (2002), 53(4), 251-262 CODEN: NASDA6; ISSN: 0027-7606
PUBLISHER:	Nagoya-shiritsu Daigaku Igakkai
DOCUMENT TYPE:	Journal
LANGUAGE:	Japanese

AB A possible role of the human Cdr2 in the G(2)/M **DNA** damage checkpoint mechanism, which damage is induced by UV irradn., was examd. A human Cdr2 gene was isolated from a cDNA library of HeLa cells by using an amino acid sequence of Schizosaccharomyces pombe. A northern anal. was carried out using the above entire human gene as a probe and a GAPDH cDNA fragment as a house-keeping probe. The Cdr2 **DNA** was combined at its 3'-terminal end with a Myc and His tag and the protein of the recombinant was expressed using Baculovirus Expression Vector System (PHARMINGEN). An antibody to the produced recombinant protein was obtained from an immunized rabbit. The cellular localization of Cdr2 was assayed by A172 cells and an indirect fluorescent antibody method, and the cellular nucleus was stained with DAPI. An expression vector with the recombinant **DNA** was introduced into HeLa S2 cells by using a Mirus Trans IT-CT1 kit (Mirus). The recombinant Cdr2 was overexpressed in the transformed cells. The cells was treated with 70% ethanol, stained with propidium iodide and an FACS anal. was carried out. A cell cycle was

analyzed based on contents of **DNA**. The Cdr2 protein was found in almost any tissue. The mRNA of Cdr2 was found at any phase of the cell cycle. The Cdr2 specifically phosphorylated a Ser 216 residue of Cdc25C and a Ser 361 residue of Cdc25B. The Cdr2 was specifically activated by UV irradn. and transferred in a cellular nucleus. The excessively expressed Cdr2 induced a stop of G2/M phase. It was suggested that the Cdr2 in cells with UV irradn. regulates possibly the stop of G2/M phase.

L4 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:946484 HCAPLUS
DOCUMENT NUMBER: 138:35288
TITLE: Human homolog of yeast protein kinase Cdr2, cDNA cloning, and uses in drug screening
INVENTOR(S): Nakanishi, Makoto
PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002099110	A1	20021212	WO 2002-JP5411	20020603
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1396545	A1	20040310	EP 2002-733272	20020603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2004151713	A1	20040805	US 2003-479532	20031203
PRIORITY APPLN. INFO.:			JP 2001-168792 A	20010604
			WO 2002-JP5411 W	20020603

AB Protein kinase Cdr2 from human, encoding cDNA, recombinant expression, antisense oligonucleotide, antibodies, and use in screening of anticancer agents or drugs for treatment of injuries, are disclosed. Using rabbit polyclonal antibodies against Chk2, a cross reacting protein phosphorylated by **DNA** damage was identified. CDNA for the protein was cloned and the sequence revealed homol. to yeast Cdr2. Strong expression in brain and testis was found. HCdr2 was found to have kinase activity toward Cdc2C and Cdc2B, phosphorylating serine 216 of Cdc2C and serine 309 of Cdc2B, resp.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 MEDLINE on STN
ACCESSION NUMBER: 95394929 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7665586
TITLE: Cloning and characterization of a **human protein kinase** with homology to Ste20.
AUTHOR: Creasy C L; Chernoff J
CORPORATE SOURCE: Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
CONTRACT NUMBER: CA-09035 (NCI)
RO1 CA58836 (NCI)
SOURCE: Journal of biological chemistry, (1995 Sep 15) 270 (37) 21695-700.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-U18297
ENTRY MONTH: 199510

ENTRY DATE: Entered STN: 19951020
Last Updated on STN: 20020420
Entered Medline: 19951012

AB A **human protein kinase** (termed MST1) has been cloned and characterized. The MST1 catalytic domain is most homologous to Ste20 and other Ste20-like kinases (62-65% similar). MST1 is expressed ubiquitously, and the MST1 protein is present in all human cell lines examined. Biochemical characterization of MST1 catalytic activity demonstrates that it is a serine/threonine kinase, and that it can phosphorylate an exogenous substrate as well as itself in an in vitro kinase assay. Further characterization of the protein indicates MST1 activity increases approximately 3-4-fold upon treatment with PP2A, suggesting that MST1 is negatively regulated by phosphorylation. MST1 activity decreases approximately 2-fold upon treatment with epidermal growth factor; however, overexpression of MST1 does not affect extracellular signal-regulated kinase-1 and -2 activation. MST1 is unaffected by heat shock or high osmolarity, indicating that it is not involved in the stress-activated or high osmolarity glycerol signal transduction pathways. Thus MST1, although homologous to a member of a yeast MAPK cascade, is not involved in the regulation of a known mammalian MAPK pathway and potentially regulates a novel signaling cascade.

L4 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:293695 HCAPLUS
DOCUMENT NUMBER: 129:12726
TITLE: Identification of drugs using complementary combinatorial libraries
INVENTOR(S): Fowlkes, Dana M.; Kay, Brian K.; Frelinger, Jeffrey A.; Hyde-Deruyscher, Robin Parish
PATENT ASSIGNEE(S): Novalon Pharmaceutical Corp., USA; Fowlkes, Dana M.; Kay, Brian K.; Frelinger, Jeffrey A.; Hyde-Deruyscher, Robin Parish
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9819162	A1	19980507	WO 1997-US19638	19971031
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9854268	A1	19980522	AU 1998-54268	19971031
AU 744444	B2	20020221		
EP 937253	A1	19990825	EP 1997-948137	19971031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001510453	T2	20010731	JP 1998-520727	19971031
US 6617114	B1	20030909	US 1998-69827	19980430
PRIORITY APPLN. INFO.:			US 1996-740671	A2 19961031
			WO 1997-US19638	W 19971031
			US 1998-50359	A2 19980331

AB The present invention is directed to the identification of compds. in a compd. library which can mediate the biol. activity of a target receptor protein, even when the ligands which mediate that activity through binding to that receptor are not already known. The method comprises three steps: (1) screen at least one potential surrogate combinatorial library for

members (preferably peptides or nucleic acids) binding to the target protein (TP) and hence capable of use as surrogates for the unknown ligand in steps (2) and (3); (2) screen at least one complementary library, preferably a combinatorial library (which is not limited to, and may not even include, peptides, or nucleic acids and hence is referred to on occasion as a "compd. library"), for compds. which inhibit the binding of one or more surrogates from step (1) to TP; and, optionally, (3) det. whether the inhibitory compd. mediates the biol. activity of the TP. Human cytomegalovirus polymerase accessory protein UL44 was cloned and expressed as a glutathione-S-transferase (GST) fusion protein in Escherichia coli. Thrombin-cleaved UL44 or GST-UL44 was immobilized on microtiter plates for affinity selection of UL44-specific phage from phage libraries. Phage from an X10C library (a library with 10 random residues followed by a fixed cysteine residue (TGC) and the same flanking sequences) gave strong signals in a phage ELISA. Competition expts. were carried out between phage and glutathione or linear double-stranded **DNA** using microtiter plates coated with GST-UL44 to show that phage were specific for either the GST portion or the UL44 portion of the fusion protein.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:942767 HCAPLUS
DOCUMENT NUMBER: 140:40262
TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics
INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 408 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XB38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:		
US 2002-374547P	P	20020423
US 2002-420784P	P	20021024
US 2002-421043P	P	20021025
US 2002-424680P	P	20021108
WO 2002-US38221	A	20021112

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addn., reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of detg. whether a gene is correlated with a disease phenotype, where correlation is detd. using a Bayesian anal. [This abstr. record is one of three records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

L4 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:942767 HCAPLUS
DOCUMENT NUMBER: 140:40262
TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics
INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 408 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XB38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:		
US 2002-374547P	P	20020423
US 2002-420784P	P	20021024
US 2002-421043P	P	20021025
US 2002-424680P	P	20021108
WO 2002-US38221	A	20021112

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addn., reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of detg. whether a gene is correlated with a disease phenotype, where correlation is detd. using a Bayesian anal. [This abstr. record is one of three records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

L4 ANSWER 9 OF 12 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 97352731 EMBASE
DOCUMENT NUMBER: 1997352731
TITLE: On the regulation and function of human polo-like kinase 1 (PLK1): Effects of overexpression on cell cycle progression.
AUTHOR: Mundt K.E.; Golsteyn R.M.; Lane H.A.; Nigg E.A.
CORPORATE SOURCE: E.A. Nigg, Department of Molecular Biology, Sciences II, University of Geneva, Quai Ernest Ansermet 30, 1211 Geneva 4, Switzerland. erich.nigg@molbio.unige.ch
SOURCE: Biochemical and Biophysical Research Communications, (1997) 239/2 (377-385).
Refs: 41
ISSN: 0006-291X CODEN: BBRCA
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The **human protein kinase** Plk1, a member of the polo-like kinase family, is known to function at mitosis. Here we show that the relative specific activity of Plk1 increases in mitosis, that Plk1 is specifically phosphorylated during mitosis, and that **phosphatase** treatment reduces mitotic Plk1 activity to interphase levels. To identify domains involved in the regulation of Plk1 activity, deletion mutants of Plk1 were constructed and their activities examined. Deletion of the extreme C-terminus of Plk1 substantially increased kinase activity, indicating that the C-terminus harbors an inhibitory domain. Finally, the consequences of over-production of wild-type and mutant Plk1 protein were analyzed, using transient transfection assays. Cells overexpressing Plk1 protein were able to enter mitosis and establish an apparently normal bipolar spindle. In contrast, progression through mitosis was transiently delayed, and cytokinesis appeared to be disturbed, as reflected by a significant increase in large cells with multiple, often fragmented nuclei. These results are relevant to recently proposed roles for Plks during both entry into and exit from mitosis.

L4 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:650120 HCAPLUS
DOCUMENT NUMBER: 141:168962
TITLE: Single nucleotide polymorphisms as predictive diagnostics for adverse drug reactions and drug efficacy
INVENTOR(S): Stropp, Udo; Schwers, Stephan; Kallabis, Harald
PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany
SOURCE: PCT Int. Appl., 349 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067774	A2	20040812	WO 2004-EP539	20040123

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

PRIORITY APPLN. INFO.:	EP 2003-2212	A	20030131
	EP 2003-2153	A	20030203

AB The invention provides diagnostic methods and kits including oligonucleotide and/or polynucleotides or derivs., including as well antibodies detg. whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. Two hundred ninety-two polymorphic sites in a no. of candidate genes show a strong correlation with cardiovascular disease and to individuals exhibiting low or high levels of adverse drug reactions. The invention provides further diagnostic methods and kits including antibodies detg. whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.

L4 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:371064 HCAPLUS
DOCUMENT NUMBER: 140:373461
TITLE: Evaluation of breast cancer states and outcomes using gene expression profiles
INVENTOR(S): West, Mike; Nevins, Joseph R.; Huang, Andrew
PATENT ASSIGNEE(S): Synpac, Inc., USA
SOURCE: PCT Int. Appl., 799 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037996	A2	20040506	WO 2003-US33656	20031024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004083084	A1	20040429	US 2002-291878	20021112
US 2004106113	A1	20040603	US 2002-291886	20021112

PRIORITY APPLN. INFO.:

US 2002-420729P	P	20021024
US 2002-421062P	P	20021025
US 2002-421102P	P	20021025
US 2002-424701P	P	20021108
US 2002-424715P	P	20021108
US 2002-424718P	P	20021108
US 2002-291878	A	20021112
US 2002-291886	A	20021112
US 2002-425256P	P	20021112
WO 2002-US38216	A	20021112
WO 2002-US38222	A	20021112
US 2003-448461P	P	20030221
US 2003-448462P	P	20030221
US 2003-457877P	P	20030327
US 2003-458373P	P	20030331

AB The present invention relates generally to a method for evaluating and/or predicting breast cancer states and outcomes by measuring gene and metagene expression levels and integrating such data with clin. risk factors. Genes and metagenes whose expressions are correlated with a particular breast cancer risk factor or phenotype are provided using binary prediction tree modeling. The invention provides 175 genes assocd. with metagene predictors of lymph node metastasis, 216 genes assocd. with metagene predictors of breast cancer recurrence, and 496 metagenes related

to breast cancer study. Methods of using the subject genes and metagenes in diagnosis and treatment methods, as well as drug screening methods, etc are also provided. In addn., reagents, media and kits that find use in practicing the subject methods are also provided.

L4 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:285562 HCAPLUS
DOCUMENT NUMBER: 137:61578
TITLE: Expressed gene sets as markers for specific tumors
INVENTOR(S): Ramaswamy, Sridhar; Golub, Todd B.; Tamayo, Pablo; Angelo, Michael
PATENT ASSIGNEE(S): Whitehead Institute for Biomedical Research, USA; Dana-Farber Cancer Institute, Inc.
SOURCE: PCT Int. Appl., 715 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024956	A2	20020328	WO 2001-XB29287	20010919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002024956	A2	20020328	WO 2001-US29287	20010919
WO 2002024956	C1	20030306		
WO 2002024956	A3	20030626		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
US 2000-233534P P 20000919
US 2001-278749P P 20010326
WO 2001-US29287 W 20010919

AB Sets of genetic markers for specific tumor classes are described, as well as methods of identifying a biol. sample based on these markers. Total RNA was isolated from .apprx.300 human tumor and normal tissue specimens representing 30 individual classes of tumor or normal tissue, and cDNA produced using established mol. biol. protocols was hybridized to two high d. Affymetrix oligonucleotide microarrays (Hu6800FL and Hu35KsubA0). Raw expression data was combined into a master data set contg. the expression values for between 6800 and 16,000 genes expressed by each individual sample. A filter was applied to this data set which only allows those genes expressed at 3-fold above baseline and with an abs. difference in expression value of 100 to pass. By comparing the sets of genes which are expressed specifically in one class of tumor (e.g., pancreatic adenocarcinoma) vs. its accompanying normal tissue (e.g., normal pancreas), sets of genes were detd. which are specific to various tumors and their normal tissue counterparts. Also described are diagnostic, prognostic, and therapeutic screening uses for these markers, as well as oligonucleotide arrays comprising these markers. [This abstr. record is one of 4 records for this document necessitated by the large no. of index

entries required to fully index the document and publication system constraints.].

=> d his

(FILE 'HOME' ENTERED AT 11:54:56 ON 03 SEP 2004)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS' ENTERED AT 11:55:42 ON 03 SEP 2004

L1 502 S HUMAN PROTEIN KINASE AND DNA
L2 374 DUP REM L1 (128 DUPLICATES REMOVED)
L3 12 S L2 AND PHOSPHATASE
L4 12 FOCUS L3 1-

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.05	40.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.00	-7.00

STN INTERNATIONAL LOGOFF AT 11:57:37 ON 03 SEP 2004

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 10 of 28 returned.

☐ 1. Document ID: US 20040147586 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 28 File: PGPB Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040147586
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040147586 A1

TITLE: Indolinone derivatives as protein kinase/phosphatase inhibitors

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tang, Peng Cho	Moraga	CA	US	
Harris, G. Davis	San Francisco	CA	US	
Li, Xiaoyuan	Los Altos	CA	US	

US-CL-CURRENT: 514/414; 548/455

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20040127538 A1

L1: Entry 2 of 28 File: PGPB Jul 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040127538
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040127538 A1

TITLE: Novel 1h-indazole compound

PUBLICATION-DATE: July 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Oinuma, Hitoshi	Ibaraki		JP	
Ohi, Norihito	Ibaraki		JP	
Sato, Nobuaki	Ibaraki		JP	
Soejima, Motohiro	Ibaraki		JP	
Seshimo, Hidenori	Saitama		JP	

Terauchi, Taro	Ibaraki	JP
Doko, Takashi	Ibaraki	JP
Kohmura, Naohiro	Ibaraki	JP

US-CL-CURRENT: 514/406; 548/361.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 3. Document ID: US 20040067531 A1

L1: Entry 3 of 28 File: PGPB Apr 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040067531
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040067531 A1

TITLE: Methods of modulating protein tyrosine kinase function with substituted indolinone compounds

PUBLICATION-DATE: April 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tang, Peng Cho	Moraga	CA	US	
Sun, Li	Foster City	CA	US	
Tran, Ngoc My	Mountain View	CA	US	
Nguyen, Anh Thi	Fremont	CA	US	
Nematalla, Asaad	Brinda	CA	US	

US-CL-CURRENT: 435/7.1; 514/291, 514/411, 546/81, 548/427, 548/429

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 4. Document ID: US 20040002534 A1

L1: Entry 4 of 28 File: PGPB Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002534
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002534 A1

TITLE: Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lipson, Ken	San Mateo	CA	US	
McMahon, Gerald	Kenwood	CA	US	

US-CL-CURRENT: 514/414; 514/418

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 5. Document ID: US 20030208067 A1

L1: Entry 5 of 28 File: PGPB Nov 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030208067
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030208067 A1

TITLE: Inhibitors of protein kinase for the treatment of disease

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cao, Sheldon Xiaodong	Carlsbad	CA	US	
Dumas, David Paul	San Diego	CA	US	
Chen, Xiaohua	San Diego	CA	US	
Yang, Jae Young	Carlsbad	CA	US	

US-CL-CURRENT: 544/59; 544/162, 544/181, 544/224, 544/335, 544/336, 546/332, 548/205, 548/247, 548/335.5, 548/375.1, 548/503, 549/491, 549/66, 564/36

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 6. Document ID: US 20030203901 A1

L1: Entry 6 of 28 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203901
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030203901 A1

TITLE: Methods of modulating tyrosine protein kinase function with indolinone compounds

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tang, Peng Cho	Moraga	CA	US	
Sun, Li	Foster City	CA	US	

US-CL-CURRENT: 514/228.2; 514/234.5, 514/243, 514/248, 514/250, 514/267, 514/291, 544/184, 544/234, 544/251, 544/345, 544/60, 546/82

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 7. Document ID: US 20030187007 A1

L1: Entry 7 of 28 File: PGPB Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030187007
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030187007 A1

TITLE: Inhibitors of protein kinase for the treatment of disease

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cao, Sheldon Xiaodong	Carlsbad	CA	US	
Bounaud, Pierre-Yves	San Diego	CA	US	
Chen, Xiaohua	San Diego	CA	US	
Chung, Hyun-Ho	San Diego	CA	US	
KC, Sunil Kumar	San Diego	CA	US	
Min, Changhee	San Diego	CA	US	
Yang, Jae Young	Carlsbad	CA	US	
Long, Melissa C.	San Diego	CA	US	

US-CL-CURRENT: 514/277; 514/408, 514/622, 514/678, 514/736, 546/339, 548/557, 560/130, 560/138, 564/158, 568/333, 568/744

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 8. Document ID: US 20030181480 A1

L1: Entry 8 of 28 File: PGPB Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030181480
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030181480 A1

TITLE: Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
McMahon, Gerald	San Francisco	CA	US	
Weinberger, Heinz	Sulzbach/Ts	CA	DE	
Kutscher, Bernhard	Maintal		DE	
App, Harald	San Francisco		US	

US-CL-CURRENT: 514/301; 514/302, 514/303, 546/113, 546/114, 546/115

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 9. Document ID: US 20030170767 A1

L1: Entry 9 of 28 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170767
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170767 A1

TITLE: Fluorescent protein sensors of post-translational modifications

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cubitt, Andrew B.	San Diego	CA	US	

US-CL-CURRENT: 435/15; 435/23, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 10. Document ID: US 20020197606 A1

L1: Entry 10 of 28 File: PGPB Dec 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020197606
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020197606 A1

TITLE: Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides

PUBLICATION-DATE: December 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Craig, Roger	Smallwood		GB	

US-CL-CURRENT: 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
protein phosphatase protein kinase	28

Display Format: - Change Format

Previous Page Next Page Go to Doc#

L1: Entry 12 of 28 File: PGPB Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020162127
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020162127 A1

TITLE: Human protein kinase domain-containing protein

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gu, Yizhong	Cupertino	CA	US	
Nguyen, Cung-Tuong	San Jose	CA	US	

US-CL-CURRENT: 800/8; 424/146.1, 435/194, 435/320.1, 435/325, 435/69.1, 514/44, 530/388.26, 536/23.2

CLAIMS:

What is claimed is:

1. An isolated nucleic acid that encodes a Serine/Threonine/Tyrosine protein kinase, comprising: (a) a nucleotide sequence selected from the group consisting of: (i) SEQ ID NO: 1; (ii) the complement of the sequences set forth in (i); (iii) the nucleotide sequence of SEQ ID NO: 2; (iv) a degenerate variant of the sequences set forth in (iii); and (v) the complement of the sequences set forth in (iii) and (iv); or (b) a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence that encodes a polypeptide having the sequence of SEQ ID NO: 3; (ii) a nucleotide sequence that encodes a polypeptide having the sequence of SEQ ID NO: 3, with conservative amino acid substitutions; and (iii) the complement of the sequences set forth in (i) and (ii), wherein said isolated nucleic acid comprising a nucleotide sequence selected from group (b) is no more than about 100 kb in length.

2. The isolated nucleic acid of claim 1 wherein said nucleic acid, or the complement of said nucleic acid, encodes a polypeptide having Serine/Threonine/Tyrosine protein kinase activity.

3. The isolated nucleic acid of claim 1, wherein said nucleic acid, or the complement of said nucleic acid, is expressed in adult liver, bone marrow, brain, colon, fetal liver, heart, kidney, lung, placenta, and skeletal muscle as well as a cell line HeLa.

4. A nucleic acid probe, comprising the nucleic acid of claim 1.

5. The probe of claim 4, wherein said probe is detectably labeled.

6. The probe of claim 4, attached to a substrate.

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, September 03, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
☐	L5	L4 and dna	22
☐	L4	human protein kinase.clm.	24
☐	L3	protein phosphatase protein kinase.clm.	0
☐	L2	L1 and pphkp	0
☐	L1	protein phosphatase protein kinase	28

END OF SEARCH HISTORY